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Abstract
Recent advances in biological therapies have revolutionalised and redefined 
treatment targets in inflammatory bowel disease (IBD). There is now a stronger 
emphasis on achieving the more stringent therapeutic goals of mucosal and 
histological healing, rather than clinical remission alone. Consequently, the 
treatment of refractory “functional” gastrointestinal symptoms, often attributed as 
the aftermath of previous inflammation, has recently become more prominent in 
quiescent disease. With further expected advances in anti-inflammatory 
treatments on the horizon, the burden of such symptoms in quiescent disease, 
which have been relatively neglected, is set to become an even bigger problem. In 
this article, we highlight the current state of research and understanding in this 
field, including recent developments and clinical practice guidelines on the 
diagnosis and management of functional gastrointestinal symptoms, such as 
irritable bowel syndrome and functional anorectal and pelvic floor disorders, in 
patients with quiescent IBD. These disorders are not only highly prevalent in 
these patients, they are often misdiagnosed, and are difficult to treat, with very 
few evidence-based therapies. Moreover, they are associated with substantial 
impairment in quality-of-life, considerable morbidity, and psychological distress. 
There is therefore an urgent need for a change in emphasis towards earlier 
recognition, positive diagnosis, and targeted treatment for patients with ongoing 
functional gastrointestinal symptoms in the absence of active IBD. This article also 
highlights the need for further research to develop much needed evidence-based 
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Core tip: Functional gastrointestinal symptoms, in the absence of inflammation, affect 
around one-third of inflammatory bowel disease (IBD) patients in remission, causing 
significant psychological distress and impairment of quality of life. As IBD therapies 
continue to advance, functional gastrointestinal symptoms, as a consequence of previous 
inflammation, are set to become a bigger problem. Here, we review the current evidence 
base, highlight a recently proposed diagnostic algorithm, and discuss empirical treatment 
guidance for functional gastrointestinal symptoms in quiescent IBD. We also discuss 
future considerations and areas of unmet need to stimulate further research.
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INTRODUCTION
Recent advances in medical therapies for both ulcerative colitis (UC) and Crohn's 
disease (CD) have improved the frequency and depth of remission in patients with 
inflammatory bowel disease (IBD)[1]. With the current availability of biological agents 
targeting multiple disease mechanisms including anti-tumour necrosis factor-α, anti-
integrin, and anti-interleukin 12/23 drugs, as well as janus kinase inhibitors, the goals 
of IBD treatment have changed dramatically in recent years. Moreover, the 
introduction of several, more cost-effective, biosimilar drugs, have also improved 
access to some biological agents[2].
As a result of these developments, complete mucosal and histological healing, 
which appears to lead to improved outcomes for patients[3-5], has become a realistic 
therapeutic target. Consequently, clinical remission is no longer the recommended 
standard of care, and a more aggressive, “treat to target approach” , has been 
advocated[6-8]. This change in emphasis, together with the use of biochemical and 
endoscopic measures of subclinical inflammation to assess disease activity, has led to 
increasing awareness of a group of patients with IBD who have refractory 
gastrointestinal symptoms, in the absence of objective inflammation[9]. Indeed, recent 
data have shown that there is often a poor correlation between symptoms and mucosal 
inflammation in IBD[10]. Although the potential for co-existence of “functional” 
gastrointestinal symptoms in a proportion of patients with quiescent IBD was first 
described over 30 years ago[11], this group of patients has received minimal attention in 
the medical literature until relatively recently.
The pathophysiology of functional gastrointestinal disturbances in quiescent IBD is 
likely to be multifactorial, with numerous experimental studies demonstrating post-
inflammatory changes in gut motility[12-17], permeability[18,19], impaired colorectal 
function (abnormal colonic tone, rectal compliance and impaired anal sphincter 
function)[14], and visceral hypersensitivity[20-23]. With further progress in controlling 
inflammation successfully in patients with IBD anticipated, it is likely that there will be 
an even higher burden of refractory functional symptoms in IBD clinics in the future. 
However, despite overlap of functional symptoms being common in patients with 
IBD, there are limited evidence-based treatment options. This article discusses recent 
developments in this field, to highlight areas of unmet need, and suggest future 
directions and treatment paradigms.
The importance of early recognition and a positive diagnosis of functional overlap
Functional gastrointestinal disorders (FGIDs), are the most common disorders seen by 
gastroenterologists[24], affecting around 35% of the general population[25]. Based on their 
putative pathophysiology, these disorders have recently been re-defined as disorders 
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of gut-brain interaction, and there is now an increased emphasis on making a positive 
diagnosis of the majority of these conditions, using symptom-based criteria, in the 
absence of red flag symptoms[26,27]. In the general population, functional bowel 
disorders are the most common of these disorders of gut-brain interaction, affecting 
almost 30% of people[25] and, interestingly, these conditions have a similar, or even 
higher, prevalence in the IBD clinic[9,11]. Indeed, pooled prevalence data from a 2012 
meta-analysis suggested a prevalence of symptoms compatible with irritable bowel 
syndrome (IBS) of 35% in quiescent IBD, with a higher prevalence in CD compared 
with UC[28].
The majority of studies included in this meta-analysis pre-dated the availability of 
faecal calprotectin (FC) as a non-invasive biochemical marker of gut inflammation and 
therefore reported the frequency of IBS-type symptoms in patients in clinical 
remission. However, even in subsequent studies that have used markers of 
biochemical remission, such as FC, mucosal remission, or histological remission the 
proportion of patients with IBD reporting these symptoms remains in the region of 
25% to 30%[29-31]. Importantly, and consistently, these functional bowel symptoms in 
IBD are associated with significant psychological distress, and impair quality of life to 
a similar extent to that seen in patients with IBD with confirmed active gastrointestinal 
inflammation[29,32-37]. Similarly, although even less well studied, functional anorectal 
disorders[38] including evacuatory disorders[39] and faecal incontinence[40,41], are often 
reported in patients with quiescent disease[32]. In the absence of active inflammation, 
escalation of IBD therapy, including potentially inappropriate use of corticosteroids or 
immunosuppressive drugs is likely to be futile[42], leading to further patient 
dissatisfaction, costly, and carries the risk of serious adverse effects[43-47]. This 
underlines the importance of early recognition of functional gastrointestinal symptoms 
in patients with IBD.
Unlike the diagnosis of FGIDs in a non-IBD population, the diagnosis of 
overlapping FGIDs in IBD first requires some investigation, in order to exclude active 
inflammation. As recommended in a recently proposed diagnostic algorithm, a 
stepwise approach using biochemical tests including FC, followed by endoscopy and 
biopsies, or cross sectional imaging, should be followed[48]. Although not the focus of 
the current paper, it is also important to consider and, where appropriate, exclude 
treatable mimics of FGIDs, such as bile acid diarrhoea, small intestinal bacterial 
overgrowth, or pancreatic insufficiency, particularly where there are risk factors such 
as ileal disease or a history of predisposing surgical intervention[49].
Following the exclusion of active inflammation and important potential mimics, 
careful consideration should be given to the likely mechanism of symptoms, based 
upon the predominant clinical features, and recognising that there are likely to be 
several perturbations contributing to the pathophysiology. In addition to the 
traditional IBD-focused clinical history, particularly in the absence of active 
inflammation and structural pathology, screening questions for positive diagnostic 
features of FGIDs and risk factors for pelvic floor dysfunction are important[38]. These 
include IBS symptoms (abdominal pain, bloating, and altered bowel habit or stool 
form), obstructive defaecatory symptoms, including incomplete emptying, straining, 
features of overflow diarrhoea or impaction, and rectal digitation. The latter is an 
important clinical feature, which appears to be predictive of response to pelvic floor 
biofeedback[50,51]. Faecal incontinence should also be specifically screened, for as it has 
been shown to be highly prevalent in patients with IBD[52], but may be underreported 
due to embarrassment on the part of patients[53]. This approach will help identify those 
in whom pelvic floor and anorectal physiology investigations are appropriate.
Current strategies for management of functional gastrointestinal disorders in IBD
One of the most important steps in managing overlapping FGIDs in this context is 
optimising the patient-provider relationship, providing clear, understandable 
explanations, and a positive diagnosis. This is likely to improve acceptance of the 
diagnosis, engagement with treatment, and also helps manage expectations, all of 
which are important in achieving a positive clinical outcome.
As highlighted in a recent expert review[48], there are very few randomised 
controlled trials or prospective studies on the management of functional 
gastrointestinal symptoms in IBD. Current practice is therefore largely empirical, and 
often based upon the central tenets of IBS management using dietary, 
pharmacological, or psychological approaches (Table 1). One of the interventions with 
some evidence in clinical trials, as well as in a blinded re-challenge study in quiescent 
IBD, is a diet low in fermentable oligo-, di-, or mono-saccharides, and polyols 
(FODMAPs)[54-56]. Further evidence for the low FODMAP diet in patients with 
quiescent IBD and co-existent functional gastrointestinal symptoms comes from recent 
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Table 1 Therapies empirically used to treat functional gastrointestinal symptoms in inflammatory bowel disease requiring validation in 
future clinical trials
Treatment Gastrointestinal symptom(s) targeted
Low FODMAPs diet Bloating, visceral pain, diarrhoea
Anti-motility agents (e.g., loperamide, ondansetron) Exaggerated gastro-colic reflex, faecal urgency, diarrhoea, faecal 
incontinence
Laxatives and pro-motility agents (e.g., prucalopride, linaclotide) Slow colonic transit, constipation
Antispasmodics Visceral pain, bloating
Gut-brain neuromodulators (e.g., antidepressants) Visceral pain, faecal urgency, diarrhoea
Probiotics Bloating, altered bowel habit
Pelvic floor biofeedback Evacuatory dysfunction, faecal urgency, faecal incontinence
Psychological interventions (e.g., hypnotherapy, cognitive behavioural 
therapy)
Visceral pain, bloating, altered bowel habit, non-colonic symptoms
FODMAPs: Fermentable oligo-, di-, or mono-saccharides, and polyols.
trial data demonstrating a significantly greater improvement in gastrointestinal 
symptom scores and significantly higher rates of symptom relief after 4 wk of a low 
FODMAP diet, compared with a sham exclusion diet[57].
Unfortunately, there remains very little evidence for the efficacy of specific 
pharmacological therapies in this patient group. Current approaches include the use of 
laxatives, prokinetics, such as prucalopride in those with chronic constipation (often 
those with distal colonic disease or proctitis), antispasmodics, anti-diarrhoeal drugs, 
such as loperamide, or central neuromodulators, such as antidepressants[48]. Although 
the latter class of drugs are one of the mainstays for the treatment of abdominal 
symptoms in IBS[58], to date there has been only one randomised controlled trial in CD, 
which did not show any benefit of fluoxetine in preventing relapse of disease activity 
in patients with quiescent disease[59]. In another retrospective study, using tricyclic 
antidepressants, the authors demonstrated moderate improvement of residual 
symptoms despite “optimal” medical therapy, particularly in those with UC[60]. 
Despite the fact that certain probiotics appear beneficial in the induction and 
maintenance of UC in particular[61], their efficacy in patients with overlapping FGIDs 
and quiescent disease has not been evaluated specifically, and should be assessed in 
future clinical studies.
In patients with anorectal dysfunction, or pelvic floor dyssynergia confirmed on 
anorectal physiology, targeted pelvic floor physiotherapy and biofeedback therapy 
appear to be of benefit in several small uncontrolled studies[39,62-64], underlining the 
importance of screening for these conditions in the IBD clinic. Several psychological 
interventions have been shown to be of benefit in patients with IBS, including gut-
directed hypnotherapy[65] and cognitive behavioural therapy (CBT)[58]. Although these 
interventions may also benefit some patients with IBD, there have been few studies to 
date, most of which have not been conducted in patients with co-existent functional 
gastrointestinal symptoms[66]. Although the long-term benefits are unclear, CBT may 
have a short-term role in improving depression and quality of life in patients with IBD, 
and hypnotherapy has been shown to be of benefit in only two small studies[66,67].
CONCLUSION
Co-existent FGIDs are common in IBD, and are often under recognised and difficult to 
treat. Clinicians specialising in IBD are likely to soon become victims of their own 
success; as treatments targeting inflammation continue to improve they are likely to 
see more functional gastrointestinal symptoms, as a consequence of prior 
inflammation, in their clinics. There is therefore the need for a paradigm shift in the 
approach to some patients with IBD. Previously, in the absence of active inflammation 
as a cause for their symptoms, patients were often given reassurance that their disease 
was quiescent, but little else in the way of explanation as to why they were 
experiencing these symptoms, or how they should be managed. With improvements in 
our understanding of FGIDs in quiescent IBD, it is essential that clinicians have a 
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positive, structured, approach to managing these patients. The recent American 
Gastroenterological Association clinical practice update and diagnostic algorithm has 
helped raise awareness of these issues, and provided some much needed 
recommendations as to how to approach this group of patients[48]. There remains, 
however, an urgent need for evidence-based therapies, as most of the pharmacological 
treatment of these symptoms is empirical, and extrapolated from the IBS literature. At 
present, the key to successful management of FGIDs in IBD is recognition, early 
diagnosis, clear communication, avoidance of inappropriate escalation of IBD-related 
medications, and a careful and holistic clinical assessment to select appropriate 
patients for a low-FODMAP diet, and pelvic floor and physiology investigations. The 
latter, in the appropriate setting, may lead to targeted interventions such as 
biofeedback, which can improve symptoms as well as quality of life.
Future research should focus on developing specific evidence-based treatments for 
quiescent symptoms in IBD, based on the results of well-designed clinical trials. A 
forthcoming randomised study in the United Kingdom, funded by the National 
Institute for Health Research, has been designed to study the effectiveness of both 
dietary and pharmacological interventions in this setting. The study, a multi-arm 
multi-stage trial of a low FODMAP diet, amitriptyline, ondansetron, or loperamide, 
will include almost 500 patients with UC with ongoing diarrhoea, despite a FC < 250 
mcg/g[68]. It is anticipated that this trial will provide much needed evidence as to how 
best to manage this group of patients. In addition to identifying effective medical 
therapies, there is also a need to develop a better evidence-base for psychological and 
behavioural therapies, as well as pelvic floor interventions, with larger clinical trials in 
patients with quiescent IBD. An improved understanding of the mechanism of pelvic 
floor dysfunction in quiescent disease as a prelude to potential neuromodulatory 
therapies is also required.
REFERENCES
1 Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic 
Therapies. Immune Netw 2017; 17: 25-40 [PMID: 28261018 DOI: 10.4110/in.2017.17.1.25]
2 Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, Danese S, Peyrin-Biroulet L, 
Lakatos PL. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. 
Curr Med Chem 2019; 26: 259-269 [PMID: 28393687 DOI: 10.2174/0929867324666170406112304]
3 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, 
Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better 
predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut 2016; 65: 408-414 [PMID: 
25986946 DOI: 10.1136/gutjnl-2015-309598]
4 Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, Lorenzo A, 
Domínguez-Muñoz JE. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of 
Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis 2016; 10: 13-19 [PMID: 
26351390 DOI: 10.1093/ecco-jcc/jjv158]
5 Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi 
A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, 
Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. 
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 
3 trial. Lancet 2018; 390: 2779-2789 [PMID: 29096949 DOI: 10.1016/S0140-6736(17)32641-7]
6 Colombel JF, D'haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-
to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis 2020; 14: 254-
266 [PMID: 31403666 DOI: 10.1093/ecco-jcc/jjz131]
7 Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, 
Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, 
Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, 
Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, 
Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel 
Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015; 110: 
1324-1338 [PMID: 26303131 DOI: 10.1038/ajg.2015.233]
8 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A 
Systematic Review. Am J Gastroenterol 2019; 114: 874-883 [PMID: 30908297 DOI: 
10.14309/ajg.0000000000000183]
9 Meng J, Agrawal A, Whorwell PJ. Refractory inflammatory bowel disease-could it be an irritable bowel? 
Nat Rev Gastroenterol Hepatol 2013; 10: 58-61 [PMID: 22965430 DOI: 10.1038/nrgastro.2012.173]
10 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Poor Correlation Between 
Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in 
Inflammatory Bowel Disease. Am J Gastroenterol 2016; 111: 541-551 [PMID: 27002800 DOI: 
10.1038/ajg.2016.59]
11 Isgar B, Harman M, Kaye MD, Whorwell PJ. Symptoms of irritable bowel syndrome in ulcerative colitis in 
remission. Gut 1983; 24: 190-192 [PMID: 6826101 DOI: 10.1136/gut.24.3.190]
Mawe GM. Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon. J Clin 12
Vasant DH et al. Functional gastrointestinal disorders in IBD
WJG https://www.wjgnet.com 3717 July 14, 2020 Volume 26 Issue 26
Invest 2015; 125: 949-955 [PMID: 25729851 DOI: 10.1172/JCI76306]
13 Villanacci V, Bassotti G, Nascimbeni R, Antonelli E, Cadei M, Fisogni S, Salerni B, Geboes K. Enteric 
nervous system abnormalities in inflammatory bowel diseases. Neurogastroenterol Motil 2008; 20: 1009-
1016 [PMID: 18492026 DOI: 10.1111/j.1365-2982.2008.01146.x]
14 Bassotti G, Antonelli E, Villanacci V, Salemme M, Coppola M, Annese V. Gastrointestinal motility 
disorders in inflammatory bowel diseases. World J Gastroenterol 2014; 20: 37-44 [PMID: 24415856 DOI: 
10.3748/wjg.v20.i1.37]
15 Annese V, Bassotti G, Napolitano G, Usai P, Andriulli A, Vantrappen G. Gastrointestinal motility disorders 
in patients with inactive Crohn's disease. Scand J Gastroenterol 1997; 32: 1107-1117 [PMID: 9399391 
DOI: 10.3109/00365529709002989]
16 Peuhkuri K, Vapaatalo H, Korpela R. Even low-grade inflammation impacts on small intestinal function. 
World J Gastroenterol 2010; 16: 1057-1062 [PMID: 20205274 DOI: 10.3748/wjg.v16.i9.1057]
17 Bassotti G, Villanacci V, Nascimbeni R, Cadei M, Fisogni S, Antonelli E, Corazzi N, Salerni B. Enteric 
neuroglial apoptosis in inflammatory bowel diseases. J Crohns Colitis 2009; 3: 264-270 [PMID: 21172285 
DOI: 10.1016/j.crohns.2009.06.004]
18 Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, 
Tulic MK, Verhasselt V, Hébuterne X, Piche T. Functional bowel symptoms in quiescent inflammatory 
bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2014; 63: 744-752 
[PMID: 23878165 DOI: 10.1136/gutjnl-2012-304066]
19 Chang J, Leong RW, Wasinger VC, Ip M, Yang M, Phan TG. Impaired Intestinal Permeability Contributes 
to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing. 
Gastroenterology 2017; 153: 723-731.e1 [PMID: 28601482 DOI: 10.1053/j.gastro.2017.05.056]
20 Mueller MH, Kreis ME, Gross ML, Becker HD, Zittel TT, Jehle EC. Anorectal functional disorders in the 
absence of anorectal inflammation in patients with Crohn's disease. Br J Surg 2002; 89: 1027-1031 [PMID: 
12153630 DOI: 10.1046/j.1365-2168.2002.02173.x]
21 Andersson P, Olaison G, Hallböök O, Boeryd B, Sjödahl R. Increased anal resting pressure and rectal 
sensitivity in Crohn's disease. Dis Colon Rectum 2003; 46: 1685-1689 [PMID: 14668596 DOI: 
10.1007/BF02660776]
22 Brochard C, Siproudhis L, Ropert A, Mallak A, Bretagne JF, Bouguen G. Anorectal dysfunction in patients 
with ulcerative colitis: impaired adaptation or enhanced perception? Neurogastroenterol Motil 2015; 27: 
1032-1037 [PMID: 25940976 DOI: 10.1111/nmo.12580]
23 Loening-Baucke V, Metcalf AM, Shirazi S. Anorectal manometry in active and quiescent ulcerative colitis. 
Am J Gastroenterol 1989; 84: 892-897 [PMID: 2756980]
24 Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient 
referrals to a gastroenterology clinic. Frontline Gastroenterol 2014; 5: 266-271 [PMID: 28839783 DOI: 
10.1136/flgastro-2013-100426]
25 Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The Prevalence and Impact of 
Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, 
and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. Am J 
Gastroenterol 2018; 113: 86-96 [PMID: 29134969 DOI: 10.1038/ajg.2017.421]
26 Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and 
Rome IV. Gastroenterology 2016 [PMID: 27144617 DOI: 10.1053/j.gastro.2016.02.032]
27 Moayyedi P, Mearin F, Azpiroz F, Andresen V, Barbara G, Corsetti M, Emmanuel A, Hungin APS, Layer 
P, Stanghellini V, Whorwell P, Zerbib F, Tack J. Irritable bowel syndrome diagnosis and management: A 
simplified algorithm for clinical practice. United European Gastroenterol J 2017; 5: 773-788 [PMID: 
29026591 DOI: 10.1177/2050640617731968]
28 Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in 
inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 1474-
1482 [PMID: 22929759 DOI: 10.1038/ajg.2012.260]
29 Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC. Negative Effects on 
Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients 
With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2017; 15: 376-384.e5 [PMID: 27189912 
DOI: 10.1016/j.cgh.2016.05.012]
30 Henriksen M, Høivik ML, Jelsness-Jørgensen LP, Moum B; IBSEN Study Group. Irritable Bowel-like 
Symptoms in Ulcerative Colitis are as Common in Patients in Deep Remission as in Inflammation: Results 
From a Population-based Study [the IBSEN Study]. J Crohns Colitis 2018; 12: 389-393 [PMID: 29186372 
DOI: 10.1093/ecco-jcc/jjx152]
31 Fukuba N, Ishihara S, Tada Y, Oshima N, Moriyama I, Yuki T, Kawashima K, Kushiyama Y, Fujishiro H, 
Kinoshita Y. Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with 
clinical and endoscopic evidence of remission: prospective multicenter study. Scand J Gastroenterol 2014; 
49: 674-680 [PMID: 24646420 DOI: 10.3109/00365521.2014.898084]
32 Nigam GB, Limdi JK, Hamdy S, Vasant DH. OWE-11 The prevalence and burden of Rome IV functional 
colorectal disorders in ulcerative colitis. Gut 2019; 68: A203-A204 [DOI: 
10.1136/gutjnl-2019-BSGAbstracts.390]
33 Gracie DJ, Ford AC. Ongoing Symptoms in Ulcerative Colitis Patients in Remission: Irritable Bowel 
Syndrome or Gastrointestinal Symptoms in the Absence of Inflammation? Inflamm Bowel Dis 2017; 23: E4-
E5 [PMID: 27930410 DOI: 10.1097/MIB.0000000000000984]
34 Berrill JW, Green JT, Hood K, Campbell AK. Symptoms of irritable bowel syndrome in patients with 
inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical 
assessment of disease activity. Aliment Pharmacol Ther 2013; 38: 44-51 [PMID: 23668698 DOI: 
10.1111/apt.12335]
35 Barratt SM, Leeds JS, Robinson K, Shah PJ, Lobo AJ, McAlindon ME, Sanders DS. Reflux and irritable 
bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. 
Eur J Gastroenterol Hepatol 2011; 23: 159-165 [PMID: 21178777 DOI: 10.1097/MEG.0b013e328342a547]
Vasant DH et al. Functional gastrointestinal disorders in IBD
WJG https://www.wjgnet.com 3718 July 14, 2020 Volume 26 Issue 26
36 Perera LP, Radigan M, Guilday C, Banerjee I, Eastwood D, Babygirija R, Massey BT. Presence of Irritable 
Bowel Syndrome Symptoms in Quiescent Inflammatory Bowel Disease Is Associated with High Rate of 
Anxiety and Depression. Dig Dis Sci 2019; 64: 1923-1928 [PMID: 30725303 DOI: 
10.1007/s10620-019-05488-8]
37 Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H. Symptoms compatible with functional bowel 
disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the 
course of the disease. Therap Adv Gastroenterol 2019; 12: 1756284819827689 [PMID: 30815033 DOI: 
10.1177/1756284819827689]
38 Nigam GB, Limdi JK, Vasant DH. Current perspectives on the diagnosis and management of functional 
anorectal disorders in patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018; 11: 
1756284818816956 [PMID: 30574193 DOI: 10.1177/1756284818816956]
39 Rezaie A, Gu P, Kaplan GG, Pimentel M, Al-Darmaki AK. Dyssynergic Defecation in Inflammatory Bowel 
Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2018; 24: 1065-1073 [PMID: 
29529194 DOI: 10.1093/ibd/izx095]
40 Nigam GB, Limdi JK, Hamdy S, Vasant DH. PTH-108 The hidden burden of faecal incontinence in active 
and quiescent ulcerative colitis: an underestimated problem? Gut 2019; 68: A87-A87 [DOI: 
10.1136/gutjnl-2019-BSGAbstracts.167]
41 Gu P, Kuenzig ME, Kaplan GG, Pimentel M, Rezaie A. Fecal Incontinence in Inflammatory Bowel 
Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2018; 24: 1280-1290 [PMID: 
29617820 DOI: 10.1093/ibd/izx109]
42 Limdi JK, Vasant DH. Anorectal Dysfunction in Distal Ulcerative Colitis: Challenges and Opportunities for 
Topical Therapy. J Crohns Colitis 2016; 10: 503 [PMID: 26619892 DOI: 10.1093/ecco-jcc/jjv217]
43 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-
tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39: 447-
458 [PMID: 24444171 DOI: 10.1111/apt.12624]
44 Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in 
inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108: 
1268-1276 [PMID: 23649185 DOI: 10.1038/ajg.2013.138]
45 Lichtenstein GR, Rutgeerts P, Sandborn WJ, Sands BE, Diamond RH, Blank M, Montello J, Tang L, 
Cornillie F, Colombel JF. A pooled analysis of infections, malignancy, and mortality in infliximab- and 
immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol 2012; 107: 
1051-1063 [PMID: 22613901 DOI: 10.1038/ajg.2012.89]
46 Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, 
Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group. 
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a 
prospective observational cohort study. Lancet 2009; 374: 1617-1625 [PMID: 19837455 DOI: 
10.1016/S0140-6736(09)61302-7]
47 Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, 
Curtis JR. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With 
Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol 2018; 
113: 405-417 [PMID: 29336432 DOI: 10.1038/ajg.2017.479]
48 Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms 
in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol 2019; 17: 380-
390.e1 [PMID: 30099108 DOI: 10.1016/j.cgh.2018.08.001]
49 Barros LL, Farias AQ, Rezaie A. Gastrointestinal motility and absorptive disorders in patients with 
inflammatory bowel diseases: Prevalence, diagnosis and treatment. World J Gastroenterol 2019; 25: 4414-
4426 [PMID: 31496621 DOI: 10.3748/wjg.v25.i31.4414]
50 Patcharatrakul T, Valestin J, Schmeltz A, Schulze K, Rao SSC. Factors Associated With Response to 
Biofeedback Therapy for Dyssynergic Defecation. Clin Gastroenterol Hepatol 2018; 16: 715-721 [PMID: 
29111136 DOI: 10.1016/j.cgh.2017.10.027]
51 Vasant DH, Solanki K, Radhakrishnan NV. Rectal Digital Maneuvers May Predict Outcomes and Help 
Customize Treatment Intensity of Biofeedback in Chronic Constipation and Dyssynergic Defecation. Dis 
Colon Rectum 2017; 60: e2 [PMID: 27926570 DOI: 10.1097/DCR.0000000000000725]
52 Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect 
on quality of life. J Crohns Colitis 2013; 7: e302-e311 [PMID: 23228710 DOI: 
10.1016/j.crohns.2012.11.004]
53 Bartlett L, Nowak M, Ho YH. Reasons for non-disclosure of faecal incontinence: a comparison between 
two survey methods. Tech Coloproctol 2007; 11: 251-257 [PMID: 17676265 DOI: 
10.1007/s10151-007-0360-z]
54 Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Muir JG, Gibson PR. Consistent Prebiotic Effect on 
Gut Microbiota With Altered FODMAP Intake in Patients with Crohn's Disease: A Randomised, Controlled 
Cross-Over Trial of Well-Defined Diets. Clin Transl Gastroenterol 2016; 7: e164 [PMID: 27077959 DOI: 
10.1038/ctg.2016.22]
55 Gibson PR. Use of the low-FODMAP diet in inflammatory bowel disease. J Gastroenterol Hepatol 2017; 
32 Suppl 1: 40-42 [PMID: 28244679 DOI: 10.1111/jgh.13695]
56 Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K. Fermentable Carbohydrates 
[FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel 
Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. J Crohns Colitis 
2017; 11: 1420-1429 [PMID: 28525543 DOI: 10.1093/ecco-jcc/jjx073]
57 Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H, Levenez F, 
Pons N, Maziers N, Lomer MC, Ehrlich SD, Irving PM, Whelan K. Effects of Low FODMAP Diet on 
Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory 
Bowel Disease in a Randomized Trial. Gastroenterology 2020; 158: 176-188.e7 [PMID: 31586453 DOI: 
10.1053/j.gastro.2019.09.024]
Vasant DH et al. Functional gastrointestinal disorders in IBD
WJG https://www.wjgnet.com 3719 July 14, 2020 Volume 26 Issue 26
58 Ford AC, Lacy BE, Harris LA, Quigley EMM, Moayyedi P. Effect of Antidepressants and Psychological 
Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J 
Gastroenterol 2019; 114: 21-39 [PMID: 30177784 DOI: 10.1038/s41395-018-0222-5]
59 Mikocka-Walus A, Hughes PA, Bampton P, Gordon A, Campaniello MA, Mavrangelos C, Stewart BJ, 
Esterman A, Andrews JM. Fluoxetine for Maintenance of Remission and to Improve Quality of Life in 
Patients with Crohn's Disease: a Pilot Randomized Placebo-Controlled Trial. J Crohns Colitis 2017; 11: 
509-514 [PMID: 27664274 DOI: 10.1093/ecco-jcc/jjw165]
60 Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, Ciorba MA, Sayuk GS. 
Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin 
Gastroenterol 2014; 48: 423-429 [PMID: 24406434 DOI: 10.1097/MCG.0000000000000049]
61 Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics 
in inflammatory bowel disease. Aliment Pharmacol Ther 2017; 46: 389-400 [PMID: 28653751 DOI: 
10.1111/apt.14203]
62 Vasant DH, Limdi JK, Solanki K, Radhakrishnan NV. Biofeedback therapy improves continence in 
quiescent inflammatory bowel disease patients with anorectal dysfunction. J Gastroenterol Pancreatol Liver 
Disord 2016; 3: 1-4 [DOI: 10.15226/2374-815X/3/2/00153]
63 Perera LP, Ananthakrishnan AN, Guilday C, Remshak K, Zadvornova Y, Naik AS, Stein DJ, Massey BT. 
Dyssynergic defecation: a treatable cause of persistent symptoms when inflammatory bowel disease is in 
remission. Dig Dis Sci 2013; 58: 3600-3605 [PMID: 24026401 DOI: 10.1007/s10620-013-2850-3]
64 Khera AJ, Chase JW, Salzberg M, Thompson AJV, Kamm MA. Gut-Directed Pelvic Floor Behavioral 
Treatment for Fecal Incontinence and Constipation in Patients with Inflammatory Bowel Disease. Inflamm 
Bowel Dis 2019; 25: 620-626 [PMID: 30452638 DOI: 10.1093/ibd/izy344]
65 Vasant DH, Whorwell PJ. Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence-
base, practical aspects, and the Manchester Protocol. Neurogastroenterol Motil 2019; 31: e13573 [PMID: 
30815936 DOI: 10.1111/nmo.13573]
66 Gracie DJ, Irvine AJ, Sood R, Mikocka-Walus A, Hamlin PJ, Ford AC. Effect of psychological therapy on 
disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic 
review and meta-analysis. Lancet Gastroenterol Hepatol 2017; 2: 189-199 [PMID: 28404134 DOI: 
10.1016/S2468-1253(16)30206-0]
67 Ballou S, Keefer L. Psychological Interventions for Irritable Bowel Syndrome and Inflammatory Bowel 
Diseases. Clin Transl Gastroenterol 2017; 8: e214 [PMID: 28102860 DOI: 10.1038/ctg.2016.69]
68 Gracie DJ, Ford AC. Functional Gastrointestinal Symptoms in Inflammatory Bowel Disease: Rising to the 
Challenge. Clin Gastroenterol Hepatol 2019; 17: 572-573 [PMID: 30678841 DOI: 
10.1016/j.cgh.2018.08.039]
Published by Baishideng Publishing Group Inc 
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA 
Telephone: +1-925-3991568 
E-mail: bpgoffice@wjgnet.com 
Help Desk: https://www.f6publishing.com/helpdesk 
https://www.wjgnet.com
© 2020 Baishideng Publishing Group Inc. All rights reserved.
